

Clinical Outcomes

> 30-Day All Stroke

TCAR ROADSTER¹ Study n=219

1.4%	All Stroke
0.0%	Major Stroke
1.1%	>75yrs
0.0%	Symptomatic

HIGH SURGICAL RISK PATIENTS

CEA CREST Study n=1,240

2.3%	All Stroke
0.6%	Major Stroke ²
3.1%	>75yrs ³
3.2%	Symptomatic ²

STANDARD SURGICAL RISK PATIENTS

> Cranial Nerve Injury Rates


TCAR ROADSTER Study

0.0%	Permanent Cranial Nerve Injury
-------------	--------------------------------

CEA CREST⁴ Study

2.1%	Permanent Cranial Nerve Injury
-------------	--------------------------------

> Less Invasive



> Shorter Hospital Stays

TCAR ROADSTER Study

1.7 Days

CEA CREST⁴ Study

3.0 Days

¹ ROADSTER: J Vasc Surg. 2015 Nov;62(5):1227-34. The Silk Road System for Transcervical Access with Reversal of Flow to Perform TCAR: Results of the ROADSTER Trial - VEITH, 2016.

² N Engl J Med 2010; 363: 11-23 ³ Stroke 2011; 42(12):3484-90 ⁴ Circulation 2012; 125:2256-2264

Caution: Federal (USA) law restricts this device to sale by or on the order of a physician.

ENROUTE and the Silk Road Logo are registered trademarks of Silk Road Medical, Inc.

TCAR

TransCarotid Artery Revascularization

Clinically Proven,
Less Invasive Way
to Protect
Against Stroke




**A NEW TREATMENT OPTION
FOR CAROTID ARTERY DISEASE**

AP273.A

Treating Carotid Disease


Carotid artery disease is estimated to be the source of stroke in up to a third of cases and there are 400,000 new diagnoses of carotid artery disease made every year in the United States alone.



Carotid Artery Disease

Most cases of carotid artery disease, similar to other vascular diseases caused by atherosclerosis, are medically managed. Carotid intervention is indicated when:

- Symptomatic patients with stenosis $\geq 50\%$
- Asymptomatic patients with stenosis $\geq 80\%$




Carotid Endarterectomy

Carotid endarterectomy (CEA) has long been considered the gold standard treatment because of its low procedural stroke rate. However, CEA carries a higher risk of myocardial infarction, and cranial nerve damage due to the larger incision. Transcarotid artery revascularization (TCAR) is a new, less-invasive procedure with the lowest reported carotid stenting stroke rate of 1.4%¹.

TCAR TransCarotid Artery Revascularization


“The overall **stroke rate** of **1.4%** is the **lowest reported to date** for any prospective, multi-center trial of carotid stenting”

– J Vasc Surg 2015;62:1227-35



TCAR is a patient-friendly, endovascular procedure that incorporates the neuroprotection principles of CEA. It utilizes the ENROUTE® Transcarotid Neuroprotection System to temporarily reverse blood flow away from the brain, collecting any potential debris in the device filter, before returning the blood to a vessel in the leg. With reverse flow neuroprotection established, the ENROUTE® Transcarotid Stent is then implanted in the lesion for long-term plaque stabilization and stroke prevention.

TCAR is well-suited for patients who are at higher risk of surgical complications, due to age, medical co-morbidities, or anatomical issues. The TCAR Surveillance Project, a quality initiative led by the Society of Vascular Surgeons, has established Medicare coverage and reimbursement for symptomatic and asymptomatic patients.



Photographs on file at Silk Road Medical. Actual filter images provided by sponsored clinical trial sites. Filter debris may vary by patient.